	US 12,435,380 B2
	Compositions and methods for the diagnosis and treatment of ALT cancer
Charles P. Reynolds, Lubbock, TX (US); Balakrishna Koneru, Lubbock, TX (US); and Shawn Macha, Lubbock, TX (US)
Assigned to Texas Tech University System, Lubbock, TX (US)
Filed by Texas Tech University System, Lubbock, TX (US)
Filed on Jan. 18, 2024, as Appl. No. 18/416,668.
Application 18/416,668 is a continuation of application No. 16/979,364, granted, now 11,913,077, previously published as PCT/US2019/021502, filed on Mar. 9, 2019.
Claims priority of provisional application 62/641,218, filed on Mar. 9, 2018.
Prior Publication US 2024/0158866 A1, May 16, 2024
This patent is subject to a terminal disclaimer.
Int. Cl. C12Q 1/6886 (2018.01); A61K 31/198 (2006.01); A61K 31/439 (2006.01); A61K 45/06 (2006.01); A61P 35/00 (2006.01)

CPC C12Q 1/6886 (2013.01) [A61K 31/198 (2013.01); A61K 31/439 (2013.01); A61K 45/06 (2013.01); A61P 35/00 (2018.01); C12Q 2600/156 (2013.01)]

18 Claims

1. A method of treating a cancer in a patient, the method comprising:

administering an effective amount of at least one of PRIMA-1 or APR-246 to the patient, wherein the cancer comprises an alternative lengthening of telomeres (ALT) phenotype, and wherein the cancer is a lymphoma, a lung cancer, a breast carcinoma, a colorectal adenocarcinoma, or combinations thereof.